Dr. Joseph F. Kosinski, MD
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Medical school
- Creighton University School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 469
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: Creighton University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
TN license 42213
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Vanderbilt Clarksville Hospital Clarksville, TN
Medical groups
- Select Physical Therapy Holdings Inc (2,024 clinicians)
- Premier Medical Group PC (45 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 469
- Services billed
- 7,137
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Insertion of needle into vein for collection of blood sample | 703 | 354 |
| Established patient office or other outpatient visit, 30-39 minutes | 627 | 349 |
| Blood test, comprehensive group of blood chemicals | 549 | 333 |
| Blood test, lipids (cholesterol and triglycerides) | 526 | 324 |
| Established patient office or other outpatient visit, 20-29 minutes | 414 | 247 |
| Hemoglobin a1c level | 337 | 192 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 265 | 265 |
| Urine microalbumin (protein) analysis | 188 | 110 |
| Creatinine level to test for kidney function or muscle injury | 188 | 110 |
| Administration of influenza virus vaccine | 166 | 163 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 8 payments worth $1,500 in total to this clinician.
| Madrigal Pharmaceuticals | $1,500 |
|---|
| Travel and Lodging | $1,035 |
|---|---|
| Food and Beverage | $465 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Madrigal Pharmaceuticals Oct 20, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $807 |
| Madrigal Pharmaceuticals Oct 20, 2025 | Travel and Lodging travel to DALLAS, TX · in-kind | $228 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $187,746 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429 - A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219 - An interventional efficacy and safety phase 3 doubleblind 2ARM study to investigate orally administered ibuzatrelvir compared with placebo in nonhospitalized symptomatic adult and adolescent participants with COVID19 …
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.